Compare Abbott Laboratories (ABT) vs STMicroelectronics NV (STM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs STMicroelectronics NV — how do they compare? Abbott Laboratories trades at $95.39 (market cap $166.94B), while STMicroelectronics NV trades at $68.36 (market cap $59.25B). The key difference: Abbott Laboratories is far larger — about 2.8× STMicroelectronics NV's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | STM | |
|---|---|---|
Market Cap | $166.94B | $59.25B |
Sector | Health | Financials |
52-Week High | $136.62 | $79.91 |
52-Week Low | $82.57 | $21.20 |
Enterprise Value | $193.69B | $57.46B |
Dividend Yield | 2.63% | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
STM trades at $67.28, down 1.57% today, with a neutral technical signal and mixed earnings history. The company shows strong cash flow from operations at $2.15B in 2025 and maintains a solid balance sheet with $6.18B cash. Recent news highlights growth in AI, automotive, and industrial segments, including new product launches like the VL53L9 LiDAR module. Analyst consensus is a Buy with a $72.33 price target, indicating potential upside from current levels.
Outlook is cautiously optimistic given STM's strategic positioning in high-growth semiconductor markets, but high valuation ratios (P/E 446.19) and recent earnings misses pose risks. Revenue decline from $17.3B in 2023 to $11.8B in 2025 requires monitoring, though cost control and innovation in edge AI and automotive chips offer long-term opportunities amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
